CDXS Stock Analysis: Buy, Sell, or Hold?
CDXS - Codexis, Inc.
$1.24
-0.06 (-4.62%)
▼
HOLD
MODERATE Confidence
Last Updated: January 30, 2026
Earnings: Feb 26, 2026
25d
Get Alerted When CDXS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: CDXS shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: CDXS shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: CDXS is currently trading at $1.24, which is considered oversold relative to its 30-day fair value range of $1.51 to $1.76.
Technical Outlook: Technically, CDXS is in a strong downtrend. The price is currently testing key support at $1.22. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.6% recently.
Market Sentiment: CDXS has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $6.58 (+406.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, CDXS is in a strong downtrend. The price is currently testing key support at $1.22. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.6% recently.
Market Sentiment: CDXS has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $6.58 (+406.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$1.51 -
$1.76
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.6%
Protect Your Profits
Holding CDXS? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.6%)
- BULLISH: Trading 406.4% below Wall St target ($6.58)
- CAUTION: 5-day price weakness (-26.2%) - monitor closely
Fair Price Analysis
30-Day Fair Range
$1.51 -
$1.76
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$1.22
Resistance Level
$1.89
Current Trend
Strong Downtrend
Fundamental Context
Forward P/E (Next Year Est.)
-2.65
Wall Street Target
$6.58
(+406.4%)
Revenue Growth (YoY)
-33.0%
Profit Margin
-120.8%
Last updated: January 30, 2026 10:55 PM ET
Data refreshes hourly during market hours. Next update: 11:55 PM
Data refreshes hourly during market hours. Next update: 11:55 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CDXS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Alison Moore
SELL
6239 shares
2025-10-13
Georgia Erbez
SELL
6239 shares
2025-10-13
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$22 | 60 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1035 | 58 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$83 | 57 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$33 | 60 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
Advanced CDXS Option Strategies
Professional options setups generated by AI based on today's CDXS price and gamma walls.
